| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Dropcho), Indiana University Medical Center and The Richard Roudebush Veterans Affairs Medical Center, Indianapolis, IN; and the Biostatistics Unit (Dr. Soong), The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.
Supported by NINDS 1 P20 NS 31096, by NCI 5 P30 CA 13148, and by a Merit Review Award from the Department of Veterans Affairs.
Received December 8, 1995. Accepted in final form March 27, 1996.
Address correspondence and reprint requests to Dr. Dropcho, Department of Neurology, Indiana University Medical Center, 541 Clinical Drive, Indianapolis IN 46202-5111.
At the time of recurrence, the majority of low-grade cerebral gliomas transform to a higher grade of histologic malignancy. The purpose of this study was to determine the survival outcome for patients whose anaplastic gliomas began as low-grade tumors compared with patients with de novo high-grade gliomas. Seventy-seven (11.5%) of 667 patients with anaplastic gliomas consecutively treated at the University of Alabama at Birmingham had histologically proven prior low-grade tumors. As a group, the patients with prior low-grade tumors would be expected to have a relatively favorable outcome, as they were younger and had a lower proportion of glioblastoma multiforme than the patients with de novo anaplastic gliomas. To provide a valid comparison, we performed a matched case-control study. We matched 68 patients from the prior low-grade group one-to-one with patients from the de novo group for tumor histology, age, Karnofsky performance scores, and type of surgery, without knowledge of outcome. The two groups received comparable radiotherapy and chemotherapy. For the 68 patients with prior low-grade tumor, median actuarial survival from the time of diagnosis of malignant degeneration was 19.7 months and the 5-year survival rate was 22%, compared with 22.0 months and 28% for the 68 matched de novo patients. Kaplan-Meier survival curves for the two groups did not significantly differ (p = 0.24 by logrank test). There were no significant survival differences between the patient subsets of prior low-grade versus de novo with glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma/mixed anaplastic glioma. These data indicate that with currently available treatment options, the survival outlook for patients with anaplastic gliomas, whose tumors arose from transformation of low-grade gliomas, is equivalent to the prognosis for patients with de novo anaplastic gliomas.
NEUROLOGY 1996;47: 684-690
This article has been cited by other articles:
|
|
 |
|
  S-Y Yang, C-K Park, S-H Park, D G Kim, Y S Chung, and H-W Jung Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features J. Neurol. Neurosurg. Psychiatry, May 1, 2008; 79(5): 574 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohgaki and P. Kleihues Genetic Pathways to Primary and Secondary Glioblastoma Am. J. Pathol., May 1, 2007; 170(5): 1445 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceyssens, K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans [11C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1432 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series Ann. Onc., October 1, 2005; 16(10): 1702 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Brandes, A. Tosoni, P. Amista, L. Nicolardi, D. Grosso, F. Berti, and M. Ermani How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial Neurology, October 12, 2004; 63(7): 1281 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, P.-L. Di Patre, C. Burkhard, D. Schuler, N. M. Probst-Hensch, P. C. Maiorka, et al. Genetic Pathways to Glioblastoma: A Population-Based Study Cancer Res., October 1, 2004; 64(19): 6892 - 6899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van den Boom, M. Wolter, R. Kuick, D. E. Misek, A. S. Youkilis, D. S. Wechsler, C. Sommer, G. Reifenberger, and S. M. Hanash Characterization of Gene Expression Profiles Associated with Glioma Progression Using Oligonucleotide-Based Microarray Analysis and Real-Time Reverse Transcription-Polymerase Chain Reaction Am. J. Pathol., September 1, 2003; 163(3): 1033 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakamura, T. Watanabe, Y. Yonekawa, P. Kleihues, and H. Ohgaki Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C {->} A:T mutations of the TP53 tumor suppressor gene Carcinogenesis, October 1, 2001; 22(10): 1715 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kleihues and H. Ohgaki Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors Toxicol Pathol, January 1, 2000; 28(1): 164 - 170. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Kleihues and H. Ohgaki Primary and secondary glioblastomas: From concept to clinical diagnosis Neuro-oncol, January 1, 1999; 1(1): 44 - 51. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
